A Study to Evaluate Solriktug in Adult Participants With Asthma

Key inclusion criteria:

• Participant must be aged 18 to 75 years of age.

• Documented diagnosis of asthma at least 12 months prior to Screening.

• Participants must be on maintenance asthma medications, for at least 3 months priorto screening: inhaled corticosteroid (ICS) in combination with long-acting betaagonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist [LAMA]).

• Participant has an ACQ-6 score ≥1.5 at Screening Visit.

• Participant has FEV1 of ≥50% to 90%, inclusive, of predicted normal value atScreening Visit 1.

• Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL overthe pre-salbutamol FEV1 at Screening Visit.

Key exclusion criteria:

• Female participant who is pregnant or breastfeeding.

• Participant is a current smoker, or former smoker with a smoking history of ≥10pack-years.

• Participant has a known hypersensitivity to any component of the formulation ofsolrikitug, including any of the excipients, or a history of anaphylactic reactionto any therapeutic monoclonal antibody.

• Participant has history or evidence of any clinically significant cardiovascular,hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic,psychiatric, renal and/or other major disease or malignancy, or any other condition (risks factors of pneumonia) that in the opinion of the Investigator might obfuscatethe study data.

• Participant has an exacerbation of asthma requiring use of OCS or hospitalization inthe 6 weeks prior to Screening or during the Screening Period.

• Participant has history or evidence of any clinically significant pulmonarycondition, other than asthma.

• Lower respiratory tract infection within the 6 weeks prior to Screening.